Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: DaveAu who wrote (1897)	5/17/1999 7:37:00 PM
From: READE SMITH	Respond to of 14101

Not a claim...a fact...Pennsaid's use by Mark Messier (when he was with the Oilers) is THE reason for Glen Sather's involvement as a Dimethaid board member. IMO Pennsaid will have enormous application as a topical treatment for sports injuries. I found this out during my initial DD several years ago, following a conversation with Dr. David Gershowitz...the co-founder of DMX. To repeat some of the info previously posted... I interviewed a dozen druggists who were prescribing Pennsaid..(then called Dimethaid D)..they all reported no side effects and excellent results...the percentage of initial users who became repeat users was over 75%...this at a personal cost of $60 a pop. The inconvenience of applying lotion did not seem to be a factor. (many of the pharmacists were/are shareholders). My wife started using this lotion over two years back for a chronic achilles tendon injury, as well as arthritis in her knees and elbows. Great results and no side effects. My doctor wonders out loud why all the approvals have taken so long, given the high cost of intestinal disorders resulting from internal use of diclofenac. p.s. DMX's volatility has been an ally over the past (jeez has it really been three years)...I hold a lot of shares and my aps is now zero. I do believe that there will be one last buying opportunity before this product gets closer to market. I also believe that DMX will be a $20 stock once the immediate major milestones are met...partner...FDA/HPB/UK approval...WF-10 phase three results... This prediction was actually made by Wood Gundy several years ago following a thoughtful analysis of projected earnings. Based on this report, DMX traded at $5 for awhile...then shareholders became dissolutioned and bored. We are closer to reaching these milestones now than ever.